On November 2017, Nicox SA (Euronext Paris: FR0013018124, COX), the international ophthalmic company, reported that it will host a conference call on November 3. 2017, at 3pm CET/ 2pm UK/ 10 am ET following the announcement of the approval of VYZULTA by the U.S. FDA (Press release, NicOx, NOV 3, 2017, View Source [SID1234521545]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
To access the conference call, please dial +33 (0)1 76 77 22 74 (France) or +44 (0)330 336 9105 or +1 323 794 2423 (International) and conference code number 5961849≠. You will be able to connect 10 minutes prior to the start time.
A slide presentation in PDF format can be accessed and will be archived on the "Events and Presentations" page of Nicox’s website www.nicox.com.
A replay of the conference call will be accessible approximately two hours following completion and will be available for 7days by dialing +33 (0)1 70 48 00 94 (France) or +44 (0)207 984 7568 or +1 719-457-0820 (International) and referencing conference confirmation code 5961849≠. The replay will also be available on the "Events and Presentations" page of Nicox’s website www.nicox.com.